Neumora Therapeutics, Inc. (NMRA) stock
Close on Nov 11, 2026Market cap $88.87MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $88.87M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.00
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$212.75M
- EPS, diluted
- -$1.23
- Book value per share
- $0.24
- Diluted shares
- 185M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $0.47
- Open
- $0.48
- Day's range
- $0.45 – $0.50
- Volume
- 491,080
- Average volume (20 days)
- 2,002,845
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.83
- 52-week range
- $0.32 – $3.65
- RSI (14 days)
- 45.0
- Volatility (1 year)
- 130.5%
- Relative volume
- 0.35×
- WACC
- 8.3%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | NMRA | S&P 500 | Difference | NMRA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -0.6% | -2.4% | +1.8 pts | ||
| 3 months | -72.2% | -1.2% | −71.0 pts | ||
| Year to date | -73.6% | +12.3% | −85.9 pts | ||
| 1 year | -82.8% | +12.4% | −95.2 pts | ||
| 3 years | -95.9% | +78.8% | −174.7 pts | -65.6% | +21.4% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Neumora Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Update
- Results
- Results
- Update
About Neumora Therapeutics
Biological Products, (No Diagnostic Substances)
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for brain and centrally mediated diseases. Its pipeline spans neurodegenerative conditions, neuropsychiatric disorders, and metabolic diseases, with product candidates targeting novel mechanisms of action. Key programs include navacaprant, an oral kappa opioid receptor antagonist in Phase 3 clinical development for major depressive disorder, and NMRA-511, a vasopressin 1a receptor antagonist evaluated for agitation associated with Alzheimer’s disease. In addition, the company is advancing NMRA-898, an M4 receptor positive allosteric modulator for schizophrenia, and NMRA-215, an oral brain-penetrant NLRP3 inhibitor for obesity. As a clinical-stage development firm, it currently targets patient populations in clinical trials rather than commercial consumers.
Company profile, executives and historyNeumora Therapeutics stock: common questions
What is Neumora Therapeutics's stock price?
NMRA closed at $0.47 on Nov 11, 2026, up 1.37% on the day. Over the past 52 weeks it traded between $0.32 and $3.65.
What is Neumora Therapeutics's market cap?
Neumora Therapeutics was worth $88.87M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is NMRA's P/E ratio?
Neumora Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.23), so it has no meaningful P/E ratio.
Does Neumora Therapeutics pay a dividend?
No. Neumora Therapeutics has not paid a cash dividend over the last twelve months.
When does Neumora Therapeutics report earnings next?
Neumora Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has NMRA stock performed over the past year?
Including dividends, NMRA returned -82.8% over the past year, against +12.4% for the S&P 500.
How many NMRA shares are sold short?
7M shares were sold short at the latest FINRA report, 4.83% of the float, or 5.1 days of average trading volume.
Who are Neumora Therapeutics's competitors?
Companies most similar to Neumora Therapeutics by business, industry and size include AVXL, RLAY, ABOS, CGTX, ALEC.
See a number that looks wrong?